Clinical Trials Logo

Raynaud Syndrome clinical trials

View clinical trials related to Raynaud Syndrome.

Filter by:
  • None
  • Page 1

NCT ID: NCT05698979 Not yet recruiting - Raynaud Syndrome Clinical Trials

Evaluation of Botulinum TOXin Type A in the Treatment of Buerger's Disease

BETOX
Start date: August 30, 2023
Phase: Phase 3
Study type: Interventional

The main objective is to assess the feasibility of treatment by injecting botulinum toxin A into the hand or foot of patients with signs of critical ischemia secondary to Buerger's disease. The injection of botulinum toxin A is carried out at the end of a single session during an hospitalization. Furthermore, tolerance and effects on the disease are evaluated at 1, 3 and 6 months post injections.

NCT ID: NCT04898036 Withdrawn - Raynaud Phenomenon Clinical Trials

Phototherapy For Treatment Of Raynaud's Phenomenon

Start date: August 2022
Phase: N/A
Study type: Interventional

To determine if blue light therapy can improve the symptoms of Raynaud's phenomenon, and provide parameters for ultimately designing commercial treatment devices, an investigational stationary phototherapy unit was designed and built.

NCT ID: NCT03869008 Terminated - Raynaud Phenomenon Clinical Trials

Potential Benefit for Non Invasive Vagus Nerve Stimulation Using GammaCore in the Treatment of Raynaud's Phenomena.

Start date: April 30, 2019
Phase: N/A
Study type: Interventional

Raynaud's phenomenon (RP) is a common vascular disorder that affects approximately 10% of the general population. RP is associated with significant morbidity that may include loss of the digits due to repeated episodes of vasospasm of the digital arteries in addition to significant impairment of quality of life. It is well known that cold exposure precipitates episodes of RP, but the mechanism for cold sensitivity is not known, and treatment of RP is not satisfactory to the patients and their physicians. The goal in this study is to test the possibility that non invasive vagus nerve stimulation (nVNS) with gammaCore which is already approved by the FDA for headaches and migraines may be an effective and well tolerated therapy for Raynaud's Phenomenon.

NCT ID: NCT01291199 Completed - Raynaud Syndrome Clinical Trials

Effects of Vardenafil on Clinical Symptoms and Peripheral Blood Flow in Patients With Raynaud's Syndrome

Start date: November 2006
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to determine whether vardenafil is effective in improving clinical symptoms and peripheral blood flow in patients with primary and secondary Raynaud phenomenon.